
Cigna (CI) Stock
Major US health insurer combining insurance with pharmacy services. Here's the price, business snapshot, and what's worth knowing about Cigna in November 2026.
Cigna Corporation (CI) is a large, US‑based health‑care and services company combining traditional health insurance with pharmacy and care‑management services through its Evernorth business. Its revenue mix includes employer and individual medical plans, Medicare products, and pharmacy benefit management and care solutions. Investors typically watch member trends, medical cost inflation, price negotiations with providers and drug‑pricing dynamics — all of which can move margins and earnings. Cigna’s business is sensitive to regulation, reimbursement changes and economic cycles that affect employer-sponsored coverage. With a market capitalisation of about $82.08 billion, it’s considered a major industry participant, but not immune to competition from insurers, PBMs and new entrants. This summary is general educational information, not personalised financial advice. Investors should consider their own circumstances, risk tolerance and seek regulated advice if needed; values can fall as well as rise and past performance is not a guide to future results.
Why It’s Moving

Cigna Raises 2026 Outlook and Targets $45 EPS by 2030 as Specialty Growth Offsets Pharmacy Headwinds
- Q3 adjusted earnings per share came in at $7.98, beating consensus estimates of $7.46, driven by strength in the Healthcare segment and favorable drug mix.
- Management raised the 2026 adjusted EPS outlook to at least $30.60 and introduced a new 'Lead to One' vision targeting a 10%-14% adjusted EPS compound annual growth rate through 2030.
- CFO Ann Dennison highlighted that the specialty business will account for a larger share of earnings by 2030, helping to offset headwinds from PBM contract renewals and rebate compression.

Cigna Raises 2026 Outlook and Targets $45 EPS by 2030 as Specialty Growth Offsets Pharmacy Headwinds
- Q3 adjusted earnings per share came in at $7.98, beating consensus estimates of $7.46, driven by strength in the Healthcare segment and favorable drug mix.
- Management raised the 2026 adjusted EPS outlook to at least $30.60 and introduced a new 'Lead to One' vision targeting a 10%-14% adjusted EPS compound annual growth rate through 2030.
- CFO Ann Dennison highlighted that the specialty business will account for a larger share of earnings by 2030, helping to offset headwinds from PBM contract renewals and rebate compression.
Six-Month Growth Performance
When is the next earnings date for Cigna Corp (CI)?
The next earnings date for CI has not been confirmed yet. Based on the company's historical reporting pattern, which typically follows a quarterly cycle of approximately three months after the previous report, the expected timing is February 2027. This upcoming release will cover the fourth quarter of fiscal year 2026. Investors should monitor official announcements for the precise scheduling details.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cigna's stock with a target price of $360.2, indicating strong potential growth.
Financial Health
Cigna is performing well with strong revenue and cash flow, but faces challenges with profit margins.
Dividend
Cigna's dividend yield of 2.06% is reasonable for investors seeking income. If you invested $1000 you would be paid $20.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pharmacy & care growth
Evernorth’s pharmacy and care‑management services can drive revenue diversification and margin enhancement, though execution and pricing pressure matter.
US‑focused footprint
Cigna’s operations are primarily US‑centred, so domestic regulation and employer benefits trends heavily influence results; global shocks can still have indirect effects.
Regulation and margins
Policy shifts, reimbursement rates and drug pricing reforms can materially affect profitability — investors should factor regulatory risk into valuations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.